COPENHAGEN, Denmark, December 19 /PRNewswire/ -- The international life science engineering and consultancy company, NNE, has reached an agreement with the health care group Fresenius ProServe to acquire its subsidiary, the Germany-based engineering company Pharmaplan GmbH.
The two companies will unite under the name of NNE Pharmaplan.
Both NNE and Pharmaplan operate in the biotechnological and pharmaceutical industries, and by joining forces they will become one of the world's leading companies in that particular field of engineering.
According to NNE's President, Hans Ole Voigt, the two companies - both rooted in the pharmaceutical industry - are a perfect match.
- Our market presence, services and areas of expertise are complementary, and therefore the synergies from the merger mean that the whole will be greater than the sum of its parts, he says.
- This will enable us to pursue growth and allow NNE Pharmaplan to become the preferred partner of the international pharma and biotech industries, continues Hans Ole Voigt.
With more than 1,500 employees specialised in pharmaceutical engineering and subsidiaries and sales offices in 15 countries, NNE Pharmaplan will be able to offer an all-encompassing portfolio of consultancy and engineering services in all markets significant to the pharmaceutical industry.
- With global reach and a large, highly skilled resource pool we will be able to serve the multinational pharmaceutical companies on a worldwide basis and be a very strong candidate for executing large-scale pharmaceutical projects, says Hans Ole Voigt.
Pharmaplan supplements NNE with know-how in delivery of turnkey facilities, validation and key pharmaceutical processes, whereas NNE supplements Pharmaplan within areas such as biotechnology, cleanroom and automation. Financially, NNE Pharmaplan will have a turnover above EUR 200 million, as NNE's turnover in 2005 was EUR 163 million and Pharmaplan's EUR 49 million.
NNE Pharmaplan will be headquartered in Copenhagen, Denmark, but will have a significant European hub in Pharmaplan's current offices in Oberursel, Germany, near Frankfurt.
- From here we plan to expand our business into central Europe, which will become an increasingly important market for pharmaceutical and biotechnological companies in the course of the coming years, says Hans Ole Voigt.
The acquisition is effective as of 1 January 2007, but will have to await the final anti-trust approval before it can be finally implemented. This is anticipated to happen in the first quarter of 2007. Until then the two companies will continue to operate separately.
NNE and Fresenius ProServe have agreed not to disclose the financial terms of the acquisition.
NNE is a leading supplier of facilities, consultancy and engineering services to the international pharmaceutical and biotech industries. NNE employs 1,200 people and has local presence in Europe, Asia and USA. www.nne.biz
NNE A/SCONTACT: For further information, please contact: Jeppe Matzen, NNECommunication Consultant, +45-30750062, jppm@nne.dk
